Predict your next investment

Academic/University
unav.es

See what CB Insights has to offer

Investments

3

Partners & Customers

1

About Universidad de Navarra

Universidad de Navarra is based in Dicastillo, Spain.

Universidad de Navarra Headquarter Location

Campus Universitario

Dicastillo, 31080,

Spain

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Universidad de Navarra News

Discovery of cells that heal cardiac damage after infarction

Sep 29, 2020

Cima and the Clinica Universidad de Navarra lead an international research showing the molecular mechanisms involved in the activation of these cardiac fibroblast in the presence of cardiac damage Universidad de Navarra Credit: Cima Universidad de Navarra Pamplona (Spain), September 29th, 2020. Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction. These "restorative" cells are a subpopulation of cardiac fibroblasts that play a fundamental role in the creation of the collagen scar needed to avoid the rupture of the ventricular wall. The research also reveals the molecular mechanisms involved in the activation of these cells and the regulation of their function. This finding, in which basic and clinical researchers have participated, will permit the identification of new therapeutic targets and the development of targeted therapies which will control the healing process of the heart after infarction. The study has been published in the latest issue of the journal Circulation, the leading scientific journal of the American Heart Association. Characterization of the reparative cardiac fibroblasts Cardiac fibroblasts are one of the fundamental components of the heart. These cells play an essential role in maintaining the structure and mechanism of this vital organ. "Recent studies have shown that fibroblasts do not respond homogeneously to heart injury. Therefore the object of our study was to determine their heterogeneity during the remodeling of the injured ventricle and to understand the mechanisms that regulate the function of these cells", said Dr Felipe Prósper, a researcher at Cima and the Clinica Universidad de Navarra, the leader of the study. "Using single-cell transcription analysis techniques (single-cell RNA-seq), we identified a subpopulation within the cardiac fibroblasts, which we have named Reparative Cardiac Fibroblasts (RCF) due to their role after the cardiac injury. We have found that, when a patient has a heart attack, these RCF are activated and offer a fibrotic response due to which a collagen scar is generated to avoid the rupture of the cardiac tissue", stated Dr Prósper, who is also a member of the Red de Terapia Celular (TerCel) and the Instituto de Investigación Sanitaria de Navarra (IdiSNA). CTHRC1, a protein related to collagen and essential for the regenerative process In the detailed molecular study, the researchers have found that the RCF have a unique transcriptional profile, that is to say, a specific information pattern for the expression of the genes involved in their cardiac function. "Among the main differential markers of the transcriptome of these cells, we have identified the CTHRC1 protein (Collagen Triple Helix Repeat Containing 1), a molecule with a fundamental role in the fibrotic response after myocardial infarction. Specifically, this protein participates in the collagen synthesis of the extracellular cardiac matrix and is crucial for the process of ventricular remodeling", in the words of Adrián Ruiz-Villalba, a researcher on the Regenerative Medicine Program at Cima and first author of the article. These results "suggest that the RCF activates the healing scar process of the cardiac lesion by secreting the CTHRC1 protein. Thus, this molecule may be considered as a biomarker associated with the physiological condition of the injured heart and a potential therapeutic target for patients who have suffered a heart attack or have dilated cardiomyopathy", stated Ruiz-Villalba, who is also a researcher at IdiSNA. In addition to Cima and the Clinica Universidad de Navarra, basic and clinical researchers from the United States, Belgium and Austria have taken part in this research. This work falls within the framework of the Cell Therapy and Regenerative Medicine research line being carried out at Cima and the Clinica Universidad de Navarra, aimed at understanding the regenerative potential of stem cells and their therapeutic application in different diseases such as cardiovascular ones. Specifically, this study is linked to the BRAV? project, an international research project combining bioengineering and cardiac stem cells to restore the function of an infarcted heart. BRAV? is an H2020 funded program by the European Union (H2020-SC1-BHC-07-2019-874827). ### Bibliographical reference: Ruiz-Villalba A. et al. Single-Cell RNA-seq Analysis Reveals a Crucial Role for Collagen Triple Helix Repeat Containing 1 (CTHRC1) Cardiac Fibroblasts after Myocardial Infarction. Circulation. 2020 Sep 25. Doi: 10.1161/CIRCULATIONAHA.119.044557. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Universidad de Navarra Investments

3 Investments

Universidad de Navarra has made 3 investments. Their latest investment was in Eversens as part of their Seed VC - II on July 7, 2020.

CBI Logo

Universidad de Navarra Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/1/2020

Seed VC - II

Eversens

$0.41M

No

1

11/9/2017

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

Subscribe to see more

0

Date

7/1/2020

11/9/2017

Round

Seed VC - II

Seed

Other Investors

Company

Eversens

Subscribe to see more

Subscribe to see more

Amount

$0.41M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

0

Universidad de Navarra Partners & Customers

1 Partners and customers

Universidad de Navarra has 1 strategic partners and customers. Universidad de Navarra recently partnered with Sener on .

Date

Type

Business Partner

Country

News Snippet

Sources

Partner

Spain

Teaching partnership with TECNUN ~ Noticias SENER

This initiative falls within SENER 's longstanding partnership with Universidad de Navarra , where it also participates in conferences and congresses.n

1

Date

Type

Partner

Business Partner

Country

Spain

News Snippet

Teaching partnership with TECNUN ~ Noticias SENER

This initiative falls within SENER 's longstanding partnership with Universidad de Navarra , where it also participates in conferences and congresses.n

Sources

1

Universidad de Navarra Team

1 Team Member

Universidad de Navarra has 1 team member, including current Managing Director, Gustavo Pego.

Name

Work History

Title

Status

Gustavo Pego

Managing Director

Current

Name

Gustavo Pego

Work History

Title

Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.